Trials / Completed
CompletedNCT03618030
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Adult Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Adults With ADHD
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 288 (actual)
- Sponsor
- Purdue Pharma, Canada · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRC-063 oral capsules | Daily dose |
| DRUG | Placebo oral capsules | Daily dose |
Timeline
- Start date
- 2018-08-21
- Primary completion
- 2019-07-05
- Completion
- 2019-07-05
- First posted
- 2018-08-07
- Last updated
- 2021-07-26
- Results posted
- 2021-07-26
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03618030. Inclusion in this directory is not an endorsement.